A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment
- 34 Downloads
Our aim is identify a new approach to vocal cord leukoplakia treatment and detect to efficiency of proton pump inhibitors.
Prospective, nonrandomized experimental clinical trial.
A ‘First Assessment Scale’ was prepared. This scale included the lesion’s and the patient’s characteristics. Using this scale, 24 patients included to the study. 20 mg rabeprazole twice daily was applied to all patients. At the end of 3rd month, a ‘Second Assessment Scale’ was used and two groups created. In group 1, 19 patients were accepted to responsive for the therapy and received the same therapy. The group 2 was included five patients that accepted unresponsive to treatment and directed to surgery. All patients received the same treatment additionally 3 months. At the end of 6th month, the Reflux Symptom Index (RSI), the Reflux Finding Score (RFS) and the Red–Green–Blue (RGB) values evaluated and comparisons were made.
The RSI and RFS values were significantly decreased in all patients. The Red values were significantly decreased with treatment in group 1, but the Green and Blue values were not. In group 2, the RGB values were not showed the significant differences. In conclusion, seven patients (29,2%) showed complete lesion regression, 12 patients (50%) showed partial lesion regression and five patients (20,8%) showed no response to treatment.
The proton pump inhibitor treatment may be beneficial for the selected patients. The scales that we prepared were useful for lesion assesment.
KeywordsVocal cord leukoplakia Laryngopharyngeal reflux Rabeprazole Proton pump inhibitor Leukoplakia Precancerous
This study was not funded.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Durant G (1880) Case of cancer of the larynx. Arch Otolaryngol 1:61–62, 1880Google Scholar
- 2.Jackson C (1923) Cancer of the larynx: Is ıt preceded by a recognızable precancerous condıtıon? Ann Surg 77(1):1–14Google Scholar
- 5.Chen M, Cheng L, Li C-J, Chen J, Shu Y-L, Wu H-T (2017) Nonsurgical Treatment for Vocal Fold Leukoplakia: An Analysis of 178 Cases. Biomed Res Int 2017:6958250Google Scholar
- 6.Ricci G, Molini E, Faralli M, Simoncelli C (2003) Retrospective study on precancerous laryngeal lesions: long-term follow-up. Acta Otorhinolaryngol Ital 23(5):362–367Google Scholar
- 7.Zhu H, Xu W, Li Y, Cheng L (2014) Observation of clinicopathological characteristics of vocal fold leukoplakia and laryngopharyngeal reflux. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 49(5):368–373Google Scholar
- 13.Galli J, Calo L, Agostino S, Cadoni G, Sergi B, Cianci R et al (2003) Bile reflux as possible risk factor in laryngopharyngealinflammatory and neoplastic lesions. Acta Otorhinolaryngol Ital 23:377–382Google Scholar
- 15.Tan JJ et al (2016) The expression and significance of pepsin in laryngeal carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 51(8):593–599Google Scholar
- 16.Li X, Huang Z, Wu T, Wang L, Wu J (2014) Role of laryngopharyngeal reflux on the pathogenesis of vocal cord leukoplakia and early glottic cancer. Zhonghua Er Bi Yan Hou Ke Za Zhi 49(5):362–367Google Scholar
- 28.Simpson CB, Archilla AS, Velazquez RA, McGuff HS (2006) Resolution of vocal fold leukoplakia with proton-pump inhibitor therapy. Ear Nose Throat J 85:362–364Google Scholar